AP540A - Paroxetine tablets and process to prepare them. - Google Patents

Paroxetine tablets and process to prepare them. Download PDF

Info

Publication number
AP540A
AP540A APAP/P/1994/000704A AP9400704A AP540A AP 540 A AP540 A AP 540A AP 9400704 A AP9400704 A AP 9400704A AP 540 A AP540 A AP 540A
Authority
AP
ARIPO
Prior art keywords
paroxetine
formulation
tablet
compressed
tablets
Prior art date
Application number
APAP/P/1994/000704A
Other languages
English (en)
Other versions
AP9400704A0 (en
Inventor
Ram Dutta Pathak
David George Doughty
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10746644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP540(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9400704A0 publication Critical patent/AP9400704A0/xx
Application granted granted Critical
Publication of AP540A publication Critical patent/AP540A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1994/000704A 1993-12-15 1994-12-13 Paroxetine tablets and process to prepare them. AP540A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939325644A GB9325644D0 (en) 1993-12-15 1993-12-15 Novel formulation

Publications (2)

Publication Number Publication Date
AP9400704A0 AP9400704A0 (en) 1995-01-31
AP540A true AP540A (en) 1996-09-20

Family

ID=10746644

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000704A AP540A (en) 1993-12-15 1994-12-13 Paroxetine tablets and process to prepare them.

Country Status (36)

Country Link
US (1) US6113944A (fr)
EP (1) EP0734260B2 (fr)
JP (1) JP3037757B2 (fr)
KR (1) KR100367796B1 (fr)
CN (1) CN1071116C (fr)
AP (1) AP540A (fr)
AT (1) ATE180973T1 (fr)
AU (1) AU697982B2 (fr)
BG (1) BG62755B1 (fr)
BR (1) BR9408219A (fr)
CA (4) CA2178637C (fr)
CZ (1) CZ287891B6 (fr)
DE (1) DE69419033T2 (fr)
DK (1) DK0734260T4 (fr)
DZ (1) DZ1835A1 (fr)
ES (1) ES2132610T5 (fr)
FI (1) FI962445A0 (fr)
GB (1) GB9325644D0 (fr)
GR (1) GR3031047T3 (fr)
HK (1) HK1012285A1 (fr)
HU (1) HUT75880A (fr)
IL (1) IL111978A (fr)
MA (1) MA23395A1 (fr)
MY (1) MY112123A (fr)
NO (1) NO307366B1 (fr)
NZ (1) NZ277790A (fr)
OA (1) OA10297A (fr)
PL (1) PL314980A1 (fr)
RO (1) RO115413B1 (fr)
RU (1) RU2146141C1 (fr)
SA (1) SA94150373B1 (fr)
SI (1) SI0734260T2 (fr)
SK (1) SK282620B6 (fr)
UA (1) UA42745C2 (fr)
WO (1) WO1995016448A1 (fr)
ZA (1) ZA949900B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2293247C (fr) 1997-06-10 2005-04-12 Synthon B.V. Composes 4-phenylpiperidine
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6168805B1 (en) 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
GB9810181D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulations
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
WO2000078290A2 (fr) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Nouvelle preparation
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2418038A1 (fr) * 2000-08-28 2002-03-07 Synthon B.V. Compositions a base de paroxetine et leurs procedes de fabrication
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
ES2280892T3 (es) 2001-07-31 2007-09-16 H. Lundbeck A/S Composicion cristalina que contiene escitalopram.
PT1440067E (pt) * 2001-10-22 2005-02-28 Synthon Bv Derivados n-formilo de paroxetina
EP1575478A2 (fr) * 2001-12-28 2005-09-21 Teva Pharmaceutical Industries Ltd. Formulation pharmaceutique d'hydrochlorure stable et procede de preparation
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
EP1761270A1 (fr) * 2004-06-23 2007-03-14 Merck & Co., Inc. Modulateurs des recepteurs d'oestrogenes
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine
EP1948646A2 (fr) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
CN109771381B (zh) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 一种帕罗西汀药物制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (fr) * 1985-10-25 1987-05-27 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
EP0269303A2 (fr) * 1986-11-11 1988-06-01 Novo Nordisk A/S Dérivés du pipéridine pour le traitement de la douleur

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50116401A (fr) * 1974-03-04 1975-09-11
ZA813205B (en) * 1980-12-05 1983-03-30 Smith Kline French Lab Dosage units
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
WO1992009281A2 (fr) * 1990-11-24 1992-06-11 Beecham Group Plc Utilisation de paroxetine pour le traitement de la demence senile, la boulimie, la migraine ou l'anorexie
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403A2 (fr) * 1985-10-25 1987-05-27 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
EP0269303A2 (fr) * 1986-11-11 1988-06-01 Novo Nordisk A/S Dérivés du pipéridine pour le traitement de la douleur

Also Published As

Publication number Publication date
IL111978A (en) 2000-07-16
CA2178637A1 (fr) 1995-06-22
MA23395A1 (fr) 1995-07-01
DK0734260T3 (da) 1999-11-15
AU697982B2 (en) 1998-10-22
DE69419033D1 (de) 1999-07-15
HK1012285A1 (en) 1999-07-30
ZA949900B (en) 1995-10-10
NO962547L (no) 1996-06-14
SK282620B6 (sk) 2002-10-08
CZ176396A3 (en) 1996-09-11
JPH09506602A (ja) 1997-06-30
WO1995016448A1 (fr) 1995-06-22
CA2274389C (fr) 2004-09-14
CZ287891B6 (cs) 2001-03-14
DK0734260T4 (da) 2008-09-29
ATE180973T1 (de) 1999-06-15
CA2214575C (fr) 1999-12-07
SI0734260T2 (sl) 2008-12-31
MY112123A (en) 2001-04-30
DE69419033T2 (de) 1999-11-25
CN1137236A (zh) 1996-12-04
GB9325644D0 (en) 1994-02-16
CA2178637C (fr) 1997-12-23
KR100367796B1 (ko) 2003-07-22
HU9601665D0 (en) 1996-08-28
US6113944A (en) 2000-09-05
EP0734260B1 (fr) 1999-06-09
SI0734260T1 (en) 1999-08-31
RU2146141C1 (ru) 2000-03-10
DZ1835A1 (fr) 2002-02-17
EP0734260A1 (fr) 1996-10-02
FI962445A (fi) 1996-06-12
CA2274389A1 (fr) 1995-06-22
NZ277790A (en) 1998-02-26
PL314980A1 (en) 1996-09-30
EP0734260B2 (fr) 2008-07-09
HUT75880A (en) 1997-05-28
BR9408219A (pt) 1997-08-26
RO115413B1 (ro) 2000-02-28
FI962445A0 (fi) 1996-06-12
JP3037757B2 (ja) 2000-05-08
CA2214575A1 (fr) 1995-06-22
SA94150373B1 (ar) 2006-05-27
SA94150373A (ar) 2005-12-03
CN1071116C (zh) 2001-09-19
AU1314595A (en) 1995-07-03
CA2274387A1 (fr) 1995-06-22
ES2132610T5 (es) 2008-12-16
NO307366B1 (no) 2000-03-27
BG100648A (bg) 1997-02-28
IL111978A0 (en) 1995-03-15
UA42745C2 (uk) 2001-11-15
NO962547D0 (no) 1996-06-14
GR3031047T3 (en) 1999-12-31
OA10297A (en) 1997-10-07
SK75696A3 (en) 1996-11-06
ES2132610T3 (es) 1999-08-16
BG62755B1 (bg) 2000-07-31
AP9400704A0 (en) 1995-01-31

Similar Documents

Publication Publication Date Title
AP540A (en) Paroxetine tablets and process to prepare them.
PL190267B1 (pl) Stała postać dawkowania do podawania doustnego zawierająca rybawirynę i sposób jej wytwarzania
US20030091628A1 (en) Formulations, tablets of paroxetine and process to prepare them
EA006826B1 (ru) Таблетки безилата амлодипина с улучшенной стабильностью
EP0429832B1 (fr) Comprimé sans libération retardée du principe actif, son procédé de préparation et utilisation de l'acide hydroxybutyrique pour la fabrication d'un tel comprimé
WO1999055698A1 (fr) Ascorbate de paroxetine
WO2021097651A1 (fr) Composition pharmaceutique comprenant de l'orlistat et un inhibiteur de lipase d'origine végétale
CZ113696A3 (en) Process for preparing peroral compositions containing quinolones
JP2702325B2 (ja) 顆粒状カルシウム組成物及びそれからなる錠剤
CN117084988A (zh) 一种盐酸喷他佐辛片及其制备方法
JP2004123731A (ja) ジオクチルソジウムスルホサクシネート配合錠剤
Plaizier-Vercammen et al. Evaluation of emcocel® 50 and emcocel® 90, a new excipient in direct compression
EA002188B1 (ru) Способ получения твёрдой композиции на основе метопролола
MXPA00010439A (en) Paroxetine ascorbate